Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Horizon Pharma plc (NASDAQ: HZNP) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Horizon Pharma plc (NASDAQ: HZNP) concerning whether a series of statements by Horizon Pharma plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On October 19, 2015, The New York Times published an article called “Drug Makers Sidestep Barriers on Pricing.” The article alleged that Horizon Pharma, along with other drug manufactures have begun using specialty pharmacies “to circumvent efforts of insurers and pharmacists to switch patients to generic components, or even to the over-the-counter versions.” Horizon Pharma was able to charge inflated prices for prescriptions by persuading doctors to submit prescriptions to affiliated mail-order specialty pharmacies.

Following this news, Horizon Pharma plc shares fell more than 20% on intraday trading on October 20, 2015.

Based in Dublin, Ireland, and founded in 2005 Horizon Pharma plc is a specialty biopharmaceutical company.

If you purchased shares of Horizon Pharma plc (NASDAQ: HZNP) on or before October 19, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185